IFAM
NBIX icon

Institutional & Family Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Institutional & Family Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500
Closed -$48K – 976
2020
Q4 		$48K Buy
+500
New +$48.3K 0.01% 333

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Institutional & Family Asset Management's NBIX Position: Q1 2021 in Review

Institutional & Family Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2021, closing a stake of 500 shares — an estimated $48K sold.

Institutional & Family Asset Management first reported a position in NBIX in Q4 2020 and held it in 1 quarter. The position peaked at $48K in Q4 2020. 420 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

  • Institutional & Family Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2021 after selling out during the quarter.
  • Institutional & Family Asset Management sold 500 Neurocrine Biosciences shares in Q1 2021, an estimated $48K.
  • Institutional & Family Asset Management first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 1 quarter.
  • Institutional & Family Asset Management's Neurocrine Biosciences position peaked at $48K in Q4 2020.
  • 420 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on Institutional & Family Asset Management's 13F filing for Q1 2021, filed 6 May 2021.